Nevirapine-d3
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534609

CAS#: 1051419-24-9

Description: Nevirapine-d3 is deuterized nevirapine, reducing P450 metabolite formation, impacting on phase II metabolism and hepatocyte protein expression.

Chemical Structure

img
Nevirapine-d3
CAS# 1051419-24-9
Instruction

Theoretical Analysis

MedKoo Cat#: 534609
Name: Nevirapine-d3
CAS#: 1051419-24-9
Chemical Formula: C15H11D3N4O
Exact Mass: 269.14
Molecular Weight: 269.322
Elemental Analysis: C, 66.90; H, 6.36; N, 20.80; O, 5.94

Price and Availability

Size Price Availability Quantity
2.5mg USD 480 2 Weeks
Bulk inquiry

Synonym: Nevirapine-d3; Nevirapine d3; Nevirapined3; 12-D3NVP; 12 D3NVP; 12D3NVP

IUPAC/Chemical Name: 2-cyclopropyl-7-(trideuteriomethyl)-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one

InChi Key: NQDJXKOVJZTUJA-FIBGUPNXSA-N

InChi Code: InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)/i1D3

SMILES Code: O=C1NC2=C(C([2H])([2H])[2H])C=CN=C2N(C3CC3)C4=C1C=CC=N4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 269.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Notter J, Bregenzer A, Vernazza P, Kahlert CR. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? Swiss Med Wkly. 2019 Apr 24;149:w20053. doi: 10.4414/smw.2019.20053. PMID: 31017649.


2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Nevirapine. 2014 Feb 2. PMID: 31644202.


3: Neary M, Chappell CA, Scarsi KK, Nakalema S, Matovu J, Achilles SL, Chen BA, Siccardi M, Owen A, Lamorde M. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. J Antimicrob Chemother. 2019 Oct 1;74(10):3003-3010. doi: 10.1093/jac/dkz298. PMID: 31299074; PMCID: PMC6753484.


4: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Nevirapine. 2020 Jan 20. PMID: 30000595.


5: Rehman N, Nguyen H. Nevirapine. 2020 Feb 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32119364.


6: Popovic M, Shenton JM, Chen J, Baban A, Tharmanathan T, Mannargudi B, Abdulla D, Uetrecht JP. Nevirapine hypersensitivity. Handb Exp Pharmacol. 2010;(196):437-51. doi: 10.1007/978-3-642-00663-0_15. PMID: 20020271.


7: Milinkovic A, Martínez E. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther. 2004 Jun;2(3):367-73. doi: 10.1586/14787210.2.3.367. PMID: 15482202.


8: Taiwo BO. Nevirapine toxicity. Int J STD AIDS. 2006 Jun;17(6):364-9; quiz 370. doi: 10.1258/095646206777323346. PMID: 16734954.


9: Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT; IMPAACT P1079 protocol team. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017 Oct 24;12(10):e0186589. doi: 10.1371/journal.pone.0186589. PMID: 29065172; PMCID: PMC5655345.


10: Awodele O, Popoola T, Rotimi K, Ikumawoyi V, Okunowo W. Antioxidant modulation of nevirapine induced hepatotoxicity in rats. Interdiscip Toxicol. 2015 Mar;8(1):8-14. doi: 10.1515/intox-2015-0002. PMID: 27486354; PMCID: PMC4961920.